Mr. Paul Averback reports

NYMOX REPORTS ON U.S. PATENT ISSUANCES

Nymox Pharmaceutical Corp. has provided an update on the issuances of several of its important U.S. patents for Nymozarfex.

The company continues to expand its patent portfolio, which is an integral part of its business. In the past 18 months, numerous newly issued patents have been granted in important jurisdictions in different parts of the world, including major markets. In the United States alone, five new patents from January, 2022, through the present time in 2023 alone have issued for the company's main business concerns, including patents for the company's treatments for prostate enlargement (benign prostatic hyperplasia) and prostate cancer. The company's chief executive officer and founder, Paul Averback, has been the inventor responsible for the company's technology and patents.

There is an important unmet need in the global middle-aged and elderly male population for effective treatment for prostate enlargement (known as BPH, or benign prostatic hyperplasia). BPH affects up to half the global male population after late middle age, and the vast majority of men have the condition when they reach their mid-70s and older. Current medical treatments are intended for lifelong treatment but are hindered by intolerable side effects that many or most men experience, and they stop treatment usually in the first year or two. These side effects can be sexual problems or a variety of other issues, some of which are more serious such as hypotension, depression, possible increased risk of prostate cancer, retrograde ejaculation and many others. Surgical treatments are effective usually but have the drawbacks of surgical pain, anesthesia, catheterizations, complications and other risks, such as the frequent permanence of retrograde ejaculation, and occasional need for retreatments.

About Nymozarfex (fexapotide)

Nymozarfex is given in an in-office procedure that is administered in a few minutes without need of anesthesia or analgesia. The drug has been tested in clinical trials involving overall more than 1,750 patients with over 1,600 injections administered, including over 1,200 fexapotide administrations. Fexapotide has led to significant long-term improvements and has shown an excellent safety profile without the side effects normally associated with existing BPH treatments.

We seek Safe Harbor.